Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00016991 · ClinicalTrials.gov registry record · Phase 2
ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse
A Phase 2 study, sponsored by Duke University.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00016991 is a Phase 2 study that has completed, run by Duke University.
The verdict
NCT00016991, a Phase 2 study, has completed, sponsored by Duke University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of glioblastoma multiforme. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have glioblastoma multiforme in first relapse.
Interventions
- DRUG gefitinib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2001-06 |
| Est. Completion | 2005-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00016991
The ClinicalTrials.gov registry entry for NCT00016991 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Duke University, which has 1,725 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which gefitinib is the first listed.
NCT00016991 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00016991 about?
NCT00016991 is a clinical study titled "ZD 1839 in Treating Patients With Glioblastoma Multiforme in First Relapse". RATIONALE: Biological therapies such as ZD 1839 may interfere with the growth of tumor cells and slow the growth of glioblastoma multiforme. PURPOSE: Phase II trial to study the effectiveness of ZD 1839 in treating patients who have glioblastoma multiforme in first relapse.
What is the current status of trial NCT00016991?
This trial is currently completed. It is a Phase 2 study. The study started on 2001-06. Estimated completion is 2005-04.
What interventions are being tested in trial NCT00016991?
The interventions under investigation include: gefitinib (DRUG).
Who is sponsoring clinical trial NCT00016991?
This trial is sponsored by Duke University, which has 1,725 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.